A 12 Weeks, Multi-center, Open Label, Randomized, Active Drug Parallel Control Trial to Compare the Effectiveness of EXforge and Nifedipine in Treating Chinese Hypertensive Patients Not Respond to Mono Antihypertensive Treatment.

Trial Profile

A 12 Weeks, Multi-center, Open Label, Randomized, Active Drug Parallel Control Trial to Compare the Effectiveness of EXforge and Nifedipine in Treating Chinese Hypertensive Patients Not Respond to Mono Antihypertensive Treatment.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Aug 2013

At a glance

  • Drugs Amlodipine/valsartan (Primary) ; Nifedipine
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms EXAM
  • Sponsors Novartis
  • Most Recent Events

    • 12 Aug 2013 Results published in Advances in Therapy.
    • 04 Oct 2012 Primary endpoint 'Diastolic-blood-pressure' has been met.
    • 04 Oct 2012 Results presented at the 24th Scientific Meeting of the International Society of Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top